secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2024-11-08T23:59:59+00:00
Accession:  0001023024-24-000100
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ANI Pharmaceuticals posts record Q3 revenue of $148.3M, raises 2024 guidance
----------------------------------------------------------------------------

- Record quarterly net revenue of $148.3M (+12.5% YoY); Cortrophin Gel revenue $52.6M (+76.8%).
- GAAP net loss of $24.2M (-$1.27 diluted EPS) vs net income of $9.5M year ago; adjusted non-GAAP EPS of $1.34.
- Completed Alimera acquisition on Sept 16, adding ILUVIEN and YUTIQ; contributed $3.9M revenue in partial quarter.
- Raised FY2024 guidance: net rev $594-602M, adjusted EBITDA $149-153M, adjusted EPS $4.90-$5.05.
- New capital structure with $316.25M 2.25% convertible notes due 2029; expected to reduce interest expense ~$39M annually.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000102302424000100/0001023024-24-000100-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000102302424000100/ani-20241108.htm
  HTML page:      https://secwatch.observer/filing/0001023024-24-000100

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer